[
  {
    "ts": null,
    "headline": "Janus Henderson Global Equity Income Fund Q4 2024 Commentary",
    "summary": "The Fund returned -4.21% and the MSCI World Index returned -0.16%. Stock selection and an underweight in healthcare contributed to relative performance.",
    "url": "https://finnhub.io/api/news?id=ca7917f0b5102cbb975e604af8457baf6b0204c906f88c7c87c3e2cc1e8d2b8b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739478840,
      "headline": "Janus Henderson Global Equity Income Fund Q4 2024 Commentary",
      "id": 132709523,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183055316/image_183055316.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "The Fund returned -4.21% and the MSCI World Index returned -0.16%. Stock selection and an underweight in healthcare contributed to relative performance.",
      "url": "https://finnhub.io/api/news?id=ca7917f0b5102cbb975e604af8457baf6b0204c906f88c7c87c3e2cc1e8d2b8b"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Cancer Treatment Misses Primary Endpoint in Trial",
    "summary": "Bristol Myers Squibb Cancer Treatment Misses Primary Endpoint in Trial",
    "url": "https://finnhub.io/api/news?id=a9a8774ce8030584659d406e11e4d99ad6b58bf3085e0defa99a54115a87f413",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739468520,
      "headline": "Bristol Myers Squibb Cancer Treatment Misses Primary Endpoint in Trial",
      "id": 132723249,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Cancer Treatment Misses Primary Endpoint in Trial",
      "url": "https://finnhub.io/api/news?id=a9a8774ce8030584659d406e11e4d99ad6b58bf3085e0defa99a54115a87f413"
    }
  }
]